Denali Therapeutics initiated with an Outperform at Baird
Baird last night initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating and $31 price target The firm believes Denali is ...
pharmaphorum3d
A history of Shire
Two years previously, TKT signed an exclusive licensing agreement with Genzyme Corporation to market Elaprase (idursulfase), which is a drug used to treat Hunter syndrome (also called MPS-II), in ...